Status In progress
Process MTA
ID number 1059

Provisional Schedule

Committee meeting: 2 09 January 2018
Expected publication 18 April 2018

Project Team

Project lead Kate Moore

Email enquiries

Consultees

Companies sponsors Bayer HealthCare (sorafenib)
  Eisai (lenvatinib)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Butterfly Thyroid Cancer Trust
  British Thryoid Foundation
Professional groups Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups National Cancer Research Institute

Timeline

Key events during the development of the guidance:

Date Update
20 November 2017 Following the technology appraisal committee meeting on 27 September 2017, NICE released an appraisal consultation document (ACD). Both companies requested to submit additional evidence at this stage, and NICE has agreed to accept this. In this instance, in line with 3.7.29 of the guide to the processes of technology appraisal that says ‘NICE may need to extend timelines and reschedule the subsequent Committee meeting to allow for new evidence to be considered,’ we need to allow the Assessment Group more time to review the additional evidence. Therefore this topic will no longer be discussed at the technology appraisal committee meeting on 23 November 2017, and has been rescheduled for 9 January 2018.
20 October 2017 - 10 November 2017 Appraisal consultation: 1
27 September 2017 Committee meeting: 1
15 August 2017 Assessment report sent for information
22 December 2016 Draft scope documents
13 December 2016 Invitation to participate
08 June 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance